Literature DB >> 18569774

Cost of disorders of the brain in Denmark.

Jes Olesen1, Patrick Sobscki, Thomas Truelsen, Dorthe Sestoft, Bengt Jönsson.   

Abstract

The cost of brain disorders in Denmark is unknown and such information is important to decision makers. The aims of the study were to estimate the total number of subjects with brain diseases, and the associated direct and indirect expenses in Denmark. This was part of a larger pan-European study commissioned by the European Brain Council, which is an international collaboration of organizations within psychiatry, neurology, neurosurgery, neuro-research and patient organizations. The project provided the best possible estimates of the expenses for brain diseases based on available international scientific literature. The present study presents results for Denmark. There were an estimated 1.4 million Danish citizens who in 2004 had one of the selected 12 brain diseases, equivalent to one quarter of the total population. Anxiety disorders and migraine were the two most frequent diseases with 500,000 and 340,000 patients, respectively. The total expenses for all selected brain diseases were 37.3 billion DKR. Affective disorders, dependency, dementia and stroke were the most costly diseases. An estimated 12% of all direct costs in the Danish health system were spent on brain diseases; 9% of the total drug consumption was used for treatment of brain diseases. Expenses to brain diseases constituted 3% of the gross domestic product. Brain disorders are very prevalent in Denmark and they cause high societal and personal cost.

Entities:  

Mesh:

Year:  2008        PMID: 18569774     DOI: 10.1080/08039480801979792

Source DB:  PubMed          Journal:  Nord J Psychiatry        ISSN: 0803-9488            Impact factor:   2.202


  6 in total

Review 1.  Economic Burden of Anxiety Disorders: A Systematic Review and Meta-Analysis.

Authors:  Alexander Konnopka; Hannah König
Journal:  Pharmacoeconomics       Date:  2020-01       Impact factor: 4.981

2.  [Development and implementation of integrated health care in pain medicine : the nationwide German headache treatment network].

Authors:  H Göbel; A Heinze; K Heinze-Kuhn; K Henkel; A Roth; H-H Rüschmann
Journal:  Schmerz       Date:  2009-12       Impact factor: 1.107

3.  Synthesis of 1,3,4-oxadiazoles derivatives with antidepressant activity and their binding to the 5-HT1A receptor.

Authors:  Shiben Wang; Lin Qi; Hui Liu; Kang Lei; Xuekun Wang; Renmin Liu
Journal:  RSC Adv       Date:  2020-08-20       Impact factor: 4.036

4.  Temporal trends in stroke admissions in Denmark 1997-2009.

Authors:  Malene Nøhr Demant; Charlotte Andersson; Ole Ahlehoff; Mette Charlot; Jonas Bjerring Olesen; Anne Gjesing; Peter R Hansen; Gunnar H Gislason; Thomas Truelsen; Christian Torp-Pedersen
Journal:  BMC Neurol       Date:  2013-10-30       Impact factor: 2.474

Review 5.  Nitric Oxide Synthase Inhibitors as Antidepressants.

Authors:  Gregers Wegener; Vallo Volke
Journal:  Pharmaceuticals (Basel)       Date:  2010-01-20

Review 6.  Myofascial trigger points in migraine and tension-type headache.

Authors:  Thien Phu Do; Gerda Ferja Heldarskard; Lærke Tørring Kolding; Jeppe Hvedstrup; Henrik Winther Schytz
Journal:  J Headache Pain       Date:  2018-09-10       Impact factor: 7.277

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.